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ABSTRACT
Objective: To determine the clinical and haematological factors associated with treatment
and outcome of chronic myeloid leukaemia (CML) at Kenyatta National Hospital.
Design: Retrospective survey of patients treated for chronic myeloid leukaemia.
Setting: Kenyatta National hospital, Nairobi, Kenya, between April 1990 and August 2000.
Subjects: Patients with chronic myeloid leukaemia.
Results: One hundred and four patients, 55 males and 49 females, age range 10-72 years
with a median age of 35 years. Treatment with busulphan getting less popular in favour
of hydroxyurea. Median follow-up 20 months with none of the clinical and haematological
parameters impacting significantly on duration of follow-up.
Conclusion: CML occurs at a younger age-group in Kenya, and none of the clinical
or haematological parameters appears to impact on follow-up duration.
INTRODUCTION
Chronic myeloid leukaemia (CML) results from
neoplastic proliferation of a multipotential
haematopoietic stem cell, with resultant proliferation of
all myeloid elements in the bone marrow and peripheral
blood. Massive enlargement of the spleen is its most
frequent clinical manifestation and profuse neutrophil
leukocytosis its most distinctive finding on peripheral
blood examination, The bone marrow picture is a
reflection of what is seen in the peripheral blood.
CML is diagnosed by the demonstration of
Philadelphia (Ph) chromosome on leukaemic cells both
in peripheral blood and the bone marrow(1). This
chromosome results from reciprocal translocation
between the long arms of chromosomes 9 and 22 –
t (91; 22) (q34; q11) (2), which results in fusion of
the ABL gene from chromosome 9 with BCR gene
from chromosome 22. This hybrid (chimeric) gene,
encodes an oncoprotein of 190, 210 or 230 kilodaltons,
depending on the breakpoint on the BCR gene. The
bcr-abl fusion protein products have enhanced tyrosine
kinase activity which is critical for leukaemogenesis(3).
Demonstration of Ph chromosome or the characteristic
ber-abl message is critical in diagnosis of CML in close
to 100% of the cases. The chronic stable phase of CML
lasts on average 24-36 months after which the acute
(blastic) phase sets in. Some cases transform first into
the accelerated phase before finally assuming the blastic
phase which is rapidly fatal within 3-6 months. The
current standard of care for CML is a combination of
interferon-alpha and cytosine arabinoside in the majority
of cases. Young patients, especially those aged less than
45-50 years are best treated with allogeneic
haematopoietic stem cell transplantation. Other agents
used are hydroxyurea or busulphan. Currently indications
are emerging that the inhibitor of the signal transduction
mediated by BCR- ABL kinase activity, STI 571
(imatinib mesylate - glivec, gleevec), should be the
standard first-line therapy for patients with CML(4,5).
We set out to evaluate in a retrospective study,
the clinical and haematological features, treatment and
outcome amongst CGL, patients at Kenyatta National
Hospital between April 1990 and August 2000 inclusive.
MATERIALS AND METHODS
Case records of patients with CML seen at Kenyatta
National Hospital between April 1990 and August 2000 were
studied. Information obtained included patients’ sex, age at
diagnosis and date of diagnosis, residence and occupation.
The size of the spleen at diagnosis was noted as massive,
moderate, tipped (mild), not palpable-haemoglobin level, total
white blood cell count at diagnosis (with differential counts
of neutrophils, monocytes, eosinophils and the blast count as
a percentage), platelet counts, and mean corpuscular volume.
Treatment given upfront was noted with response, also
second-line treatment with response. The last date of follow-
up and disease status or date of death were also recorded.
From the information obtained, duration of follow-up
was derived, and also survival duration for cases with dates
of death recorded.
Attempts were made to find out if there were any
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statistical correlations between survival or follow-up durations
with spleen size, residence, occupation, and the various
haematological parameters using the Chi-squared and student’s
t-tests.
RESULTS
Records were available for a total of 104 patients,
55 males and 49 females. The age range was 10-72
years, the median age being 35 years (Table 1). Sixty-
five patients (62.5%) were aged less than 40 years.
Eighty-eight patients out of 97 evaluable (90.7%) had
massive splenomegaly, four (4.1%) had moderate
splenomegaly, two (2.1%) had mild splenomegaly and
three (3.1%) had the spleen not palpable.
Table 1
Clinical and haematological features at diagnosis
Feature/Parameter Value/Number
Total number of patients: 104
Demographic Features:
- Number of males 55
- Number of females 49
- Median age (years) 35
- Age range (years) 10-72
Clinical Features:
- Splenomegaly (n=97)
- Massive 88 (90.7%)
- Moderate 4 (4.1%)
- Mild 2 (2.1%)
- Not palpable 3 (3.1%)
Haematological parameters (Blood):





‡ 500 19 (20.7%)
- PB blast count % (n=68)
0 2 (2.9%)
1-5 48 (70.6%)
‡6 <15 18 (26.5%)
- PB basophil count % (n=35)
<3 29 (82.9%)
‡3 6 (17.1%)











Demographic, clinical and haematologic parameters in
relation to duration of follow-up
Follow-up duration-months (n=98)
Median 20
Range <1 - 72 (312)
Follow-up duration at ‡ 2 years VS
age-group (years)
<40 years 67.5%
‡ 40 years 47.5%   P>0.I NS
Follow-up duration at ‡ 2 years VS
wbc count x 109/litre (n=92)
<100 62.5%  X2 = 4.937
‡ 100 39.4    P» 0.2 NS
Follow-up duration at ‡ 2 years VS
eosinophil count % (n=33)
< 4 37.5%  P> 0.2 NS
‡ 4 23.5%
Follow-up duration at ‡ 2 years VS
basophil count % (n=35)
<3% 27.6%
‡3% 0%
Follow-up duration at ‡ 2 years VS
blast count % (n=68)
<6 47.9% P> 0.1
‡6 50% NS
Follow-up duration at ‡ 2 years VS
haemoglobin (n=42)
<10g/dl 78.6% P > 0.1
‡ 10g/dl 60.7%NS
Follow-up duration at ‡ 2 years VS
treatment upfront (n=98)
Busulphan 44.6% P >0.1
Hydroxyurea 45.5% NS
Sixteen out of 92 patients evaluable (17.4%) had
total white blood cell counts less than 100 x 109 /litre
at diagnosis, 57 (62.1%) had counts ranging between
100-499x 109 /litre. Two out of 69 patients (2.9%)
evaluable for peripheral blood blast counts at diagnosis
had no blasts, 48 (70.6%) had blasts of 1-5% and 18(26.
5%) had blasts of ‡6% but <15%. Twenty-seven out
of 33 evaluable patients (81.8%) had peripheral blood
eosinophil counts of 4% and above, and six out of 35
(17.1%) had monocyte counts of 3% and above.
Fourteen out of 42 patients evaluable (33.3%) had
haemoglobin levels less than 10g/dl at diagnosis and
28 (66.6%) had levels of 10g/dl and above.
From 1990 -1995, 78.4% of patients were treated
with busulphan upfront and 21.6% were treated with
hydroxyurea upfront. From 1996-2000, 53.3% of the
patients were treated with busulphan upfront and 46.7%
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with hydroxyurea upfront. This shift in treatment was
significant (78.4% Vs 53.3% - P » 0.0l). No patients
were treated with interferon-alpha or cytosine
arabinoside.
Twenty nine out of 98 patients evaluable (29.6%)
were followed up for 36 months and above six (6.1%)
were followed up for 60 months and above. The median
follow-up time was 20 months, range <1-72 months.
About 46% of patients on busulphan upfront were
followed up for less than one year compared with 33%
on hydroxyurea. At 24 months an equal percentage of
patients on both treatment groups (44.6% Vs 45.8%)
were still on follow-up. Recorded time to transformation
ranged from de-novo to 36 months. Only three deaths
were recorded, the majority of the patients having been
lost to follow-up.
Twenty nine out of 61 patients aged under 40
years (47.5%) were followed up for under two years
compared with 27 out of 40 (67.5%) of those aged
40 years and above, but this difference was not
statistically significant (P> 0.1). Thirty-two out of 61
patients aged less than forty years (52.5%) were
followed up for two years and above compared with
13 out of 40 (32.5%) aged forty years and above, but
again the difference was not statistically significant.
There was no significant difference in follow-up
duration between male and female patients, either at
less than 24 months or 24 months and above (X2 =
2.499; P>0.05). When the possible impact on total
peripheral blood white cell count on duration of
follow-up was assessed, there was no difference
between those who had counts below 100 x 109/litre
and those who had counts of 100 x 109/litre and above
(X2 = 4.937, P »  0.2). Similarly, there was no
correlation between follow-up duration and peripheral
blood eosinophil, basophil and monocyte counts. Only
two patients had no baseline peripheral blood blast
counts. Those with blast counts of 1-5% and those
with 6% and above were compared and out of the
68 cases evaluable there were no significant differences
in follow up for less than two years and follow-up
of two years and above (P > 0.1). Haemoglobin levels
of 10g/dl and above or below 10g/dl were tested
against duration of follow up, but again there was no
significant difference. Platelet counts below 100 x
109/litre and those of 100 x 109/litre and above did
not correlate with duration of follow-up either.
DISCUSSION
The median age of occurrence of CML at KNH
of 35 years is a decade younger than the age of 45
years described amongst whites. The male-to-female
ratio of 1.1:1 is a known fact. Massive splenomegaly
amongst 90.7% of the patients is just on the higher side
of what is expected, possibly because our patients are
likely to present late or have health care workers delay
i  m king the diagnosis. Tropical conditions that lead
to massive splenomegaly such as visceral leishmaniasis
and chronic malarial infection could resemble CML
clinically and since they are more common this could
lead to delays in diagnosis. One can not assume that
a good peripheral blood examination is possible in all
local health institutions where these patients report first.
One should also be aware that in a retrospective study
such as this one, the accuracy of rating the spleen size
is limited.
It would appear that it is taking unnecessarily long
to set up facilities for routine chromosome banding in
our major health institutions. In absence of the capacity
to demonstrate he Philadelphia chromosome, leave
alone molecular probes for BCR/ABL fusion, our
diagnosis of CML, is based on the presence of neutrophil
leukocytosis, with full spectrum of myeloid maturation
in the peripheral blood and bone marrow. Diminished
neutrophil alkaline phosphatase score assists in making
the diagnosis. The others are serum vitamin B12 levels,
transcobalamin 1 levels and lysozymes, but they are
not assayed in our institution routinely.
The haematologic parameters in peripheral blood
in this study did not correlate with duration of follow-
up. This is not surprising since this was a retrospective
study and the follow-ups were haphazard, with the
majo ity of patients being lost to follow-up. On the
other hand, the peripheral blood parameters are not
believed to be of much prognostic value except for
persistently elevated peripheral blood blast counts.
These did not correlate with duration of follow-up
amongst our patients either.
Despite the fact that several models have been
established that could categorize patients into groups
with distinct survival characteristics(6-8), their
reproducibility and utility is doubted because they were
tried in certain generally restricted therapy regimens(9-
10). There is now evidence that histologic characteristics
of bone marrow in CML, may yield important predictors
o  dis ase progression in Philadelphia chromosome
positive CGL(11,12). Unfortunately, bone marrow
biopsies are not routinely performed for CML patients
not only in our institution, but also in most institutions
all over the world.
Traditionally, conventional chemotherapy for
CML has utilized mostly two agents, busulphan and
hydroxyurea as the standard of care. These two have
been favoured in community practice because they
are administered orally and also are relatively cheap.
Most recently, hydroxyurea has been shown to be
superior to busulphan in terms of survival duration
whether as a single agent or pre-transplant(12-14).
Busulphan is non-cell-cycle-dependent hence affects
c lls in G0 phase, bone marrow stem cells included.
This is believed to trigger off myelodysplasia and
hanc  transformation to acute leukaemia earlier.
Hy rox urea on the other hand acts mainly during
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the DNA synthetic phase of the cell cycle, with
minimal influence on non-proliferating early
haematopoietic progenitor cells. Its use is gaining
popularity in our institution as compared with
busulphan. Conventional cytotoxic drugs do not
significantly cause cytogenetic remissions in CML.
Interferon-alpha mono-therapy in maintenance on the
other hand has been shown to have significant(15,16)
or only questionable(12,13) survival advantage over
conventional chemotherapy. It induces cytogenetic
remissions in about one third of the cases of CML.
Because of high cost none of the patients in our
institution which serves mainly the poor, were treated
with interferon-alpha. Combination of cytosine
arabinoside at low doses with interferon-alpha which
has been shown to confer some survival advantage
(16) was not offered to any of these patients. Other
workers claimed survival advantage when interferon-
alpha was combined with other cytotoxic agents
either at low doses or in intensive doses, but the
value of this approach has remained
questionable(17,18).
Definitive treatment for young, fit chronic phase
CML patients with HLA - identical siblings has been
pegged on myeloablative chemotherapy with allogeneic
haematopoietic progenitor cell transplantation with 40-
70% long-term disease survivals realised. This facility
is not available to us. Luckily, imatinib mesylate
(glivec, gleevec, STI-571) is poised to become the
standard of care even in chronic stable phase CML
(4,5). Even if the cost of this agent which is currently
pegged at Kenya shillings four hundred thousand per
month (US$5335) will be a problem, this drug has the
advantages of a low side effect profile and the oral
route of administration that does not require technically
sophisticated and expensive quipment.
In conclusion, chronic myeloid leukaemia in Kenya
occurs in patients a decade younger than in the white
counterparts in Europe and North America. Clinical and
haematological parameters are similar to those described
elsewhere. The diagnostic facilities are grossly lacking
and all of our patients at KNH are treated with
conventional chemotherapies. Follow up and probably
median survival may not exceed that for untreated
patients.
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